{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:23:46Z","timestamp":1774653826018,"version":"3.50.1"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.577442","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T05:14:43Z","timestamp":1604898883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art"],"prefix":"10.3389","volume":"11","author":[{"given":"Yinhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongji","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"B1","unstructured":"Coronavirus disease 2019 (COVID-19), Situation report"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)13967-0","article-title":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome","volume":"362","author":"Kuiken","year":"2003","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25735","article-title":"Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis","volume":"92","author":"Sun","year":"2020","journal-title":"J Med Virol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/path.2067","article-title":"Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS","volume":"210","author":"He","year":"2006","journal-title":"J\u00a0Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)13413-7","article-title":"Lung pathology of fatal severe acute respiratory syndrome","volume":"361","author":"Nicholls","year":"2003","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.23.20040675","article-title":"Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARSCoV-2","author":"Yang","year":"2020","journal-title":"medRxiv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.27.20045427","article-title":"The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035876","article-title":"Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts","volume":"7","author":"Bertram","year":"2012","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","volume":"108","author":"Wang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X20500378","article-title":"COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease","volume":"48","author":"Chan","year":"2020","journal-title":"Am J Chin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2014.0227","article-title":"Disease-promoting effects of type I interferons in viral, bacterial, and coinfections","volume":"35","author":"Davidson","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7819-7826.2005","article-title":"Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis","volume":"79","author":"Cheung","year":"2005","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4166","article-title":"Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells","volume":"106","author":"Law","year":"2005","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.6.2684-2693.2006","article-title":"Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro","volume":"80","author":"Yen","year":"2006","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1371\/journal.ppat.0030005","article-title":"A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice","volume":"3","author":"Roberts","year":"2007","journal-title":"PLoS Pathog"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-09","article-title":"Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection","volume":"83","author":"Rockx","year":"2009","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2006.00942.x","article-title":"Temporal changes in cytokine\/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome","volume":"11","author":"Chien","year":"2006","journal-title":"Respirology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20255","article-title":"An interferon-gamma-related cytokine storm in SARS patients","volume":"75","author":"Huang","year":"2005","journal-title":"J Med Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00527-07","article-title":"Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome","volume":"81","author":"Cameron","year":"2007","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1001-0939.2020.03.013","article-title":"[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.12.945576%\\2020-04-0416:28:00","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","author":"Zhou","year":"2020","journal-title":"bioRxiv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/jmv.25783","article-title":"Clinical features and treatment of COVID-19 patients in northeast Chongqing","volume":"92","author":"Wan","year":"2020","journal-title":"J Med Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1086\/378587","article-title":"Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome","volume":"37","author":"Cui","year":"2003","journal-title":"Clin Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12967-020-02374-0","article-title":"Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage","volume":"18","author":"Liu","year":"2020","journal-title":"J Transl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102763","article-title":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients","volume":"55","author":"Liu","year":"2020","journal-title":"EBioMedicine"},{"key":"B40","article-title":"Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis","volume":"23","author":"Oberholzer","year":"2005","journal-title":"Shock (Augusta Ga)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.8.4410-4415.2004","article-title":"Analysis of serum cytokines in patients with severe acute respiratory syndrome","volume":"72","author":"Zhang","year":"2004","journal-title":"Infect Immun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000774","article-title":"Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients","volume":"133","author":"Ling","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000744","article-title":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province","volume":"133","author":"Liu","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jinf.2006.01.005","article-title":"Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong","volume":"54","author":"Yam","year":"2007","journal-title":"J Infect"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200306-766OC","article-title":"High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome","volume":"168","author":"Ho","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","article-title":"Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia","volume":"5","author":"Zhou","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"NEJMoa2021436","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report","author":"Group","year":"2020","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023","article-title":"Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis","volume":"324","author":"Murthy","year":"2020","journal-title":"JAMA"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00421-x","article-title":"After 62 years of regulating immunity, dexamethasone meets COVID-19","volume":"20","author":"Cain","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B51","unstructured":"People\u2019s Medical Publishing HouseGuidance for Corona Virus Disease2019"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1159\/000505099","article-title":"Interleukin-6: A Masterplayer in the Cytokine Network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01942","article-title":"Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome","volume":"11","author":"Caracciolo","year":"2020","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108598","article-title":"Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy","volume":"220","author":"Mastellos","year":"2020","journal-title":"Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2020.152001","article-title":"Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab","author":"Rambaldi","year":"2020","journal-title":"Immunobiology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42399-020-00510-x","article-title":"Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis","author":"Thangaraju","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12240","article-title":"Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): a cohort study","volume":"19","author":"Liu","year":"2015","journal-title":"Ther Apher Dial"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108408","article-title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19","volume":"214","author":"Ma","year":"2020","journal-title":"Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.05.065","article-title":"Successful recovery of severe COVID-19 with cytokine storm treating with extracorporeal blood purification","volume":"96","author":"Wang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4228","article-title":"First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA","volume":"12","author":"Padala","year":"2020","journal-title":"J Clin Med Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2020.1764369","article-title":"Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients","volume":"42","author":"Chen","year":"2020","journal-title":"Ren Fail"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102855","article-title":"Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption","volume":"59","author":"Yigenoglu","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000508125","article-title":"Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation","author":"Ronco","year":"2020","journal-title":"Blood Purif"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3785\/j.issn.1008-9292.2020.02.02","article-title":"Management of corona virus disease-19 (COVID-19): the Zhejiang experience","volume":"49","author":"Xu","year":"2020","journal-title":"J Zhejiang Univ Med Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cells8121605","article-title":"Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases","volume":"8","author":"Harrell","year":"2019","journal-title":"Cells"},{"key":"B69","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/5584_2018_306","article-title":"Molecular Mechanisms Responsible for Anti-inflammatory and Immunosuppressive Effects of Mesenchymal Stem Cell-Derived Factors","volume":"1084","author":"Harrell","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118493","article-title":"Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action","volume":"262","author":"Sadeghi","year":"2020","journal-title":"Life Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4236973","article-title":"Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives","volume":"2019","author":"Harrell","year":"2019","journal-title":"Stem Cells Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00508","article-title":"Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics","volume":"8","author":"Gao","year":"2017","journal-title":"Front Physiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/s41598-017-01836-8","article-title":"Pro-inflammatory Ca(++)-activated K(+) channels are inhibited by hydroxychloroquine","volume":"7","author":"Eugenia Schroeder","year":"2017","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.06.001","article-title":"Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19","author":"Magagnoli","year":"2020","journal-title":"Med (N Y)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","article-title":"RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","author":"Ye","year":"2020","journal-title":"J Med Virol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2020.06.003","article-title":"International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection","volume":"34","author":"Murphy","year":"2020","journal-title":"Transfus Med Rev"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117583","article-title":"COVID-19: Melatonin as a potential adjuvant treatment","volume":"250","author":"Zhang","year":"2020","journal-title":"Life Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110281","article-title":"Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming","volume":"129","author":"Chen","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.116346","article-title":"The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic","volume":"240","author":"Cao","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104820","article-title":"Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study","volume":"157","author":"Yang","year":"2020","journal-title":"Pharmacol Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0801-x","article-title":"The role played by traditional Chinese medicine in preventing and treating COVID-19 in China","volume":"14","author":"Li","year":"2020","journal-title":"Front Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104882","article-title":"The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence","volume":"157","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021404","article-title":"Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (covid-19) in 2019: Protocol for a systematic review and meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010971","article-title":"Curative efficacy and safety of traditional Chinese medicine xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: A meta-analysis","volume":"97","author":"Xiao","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12879-016-1823-5","article-title":"The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.20.03856-2","article-title":"Thymosin alpha1 alleviates lung injury in sepsis rats via notch signaling pathway","author":"Zhang","year":"2020","journal-title":"Panminerva Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2005.00245.x","article-title":"An aggressive systematic strategy for acute respiratory distress syndrome caused by severe pneumonia after renal transplantation","volume":"19","author":"Sun","year":"2006","journal-title":"Transpl Int"},{"key":"B98","article-title":"Pentaglobin in steroid-resistant severe acute respiratory syndrome","volume":"8","author":"Ho","year":"2004","journal-title":"Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746199","article-title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia","volume":"9","author":"Lin","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa022","article-title":"Correlation between immunoglobulin dose administered and plasma neutralization of streptococcal superantigens in patients with necrotizing soft tissue infections","volume":"71","author":"Bergsten","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.11.169","article-title":"Intravenous immunoglobulin (IVIg) acts directly on conventional T cells to suppress T cell receptor signaling","volume":"522","author":"Hori","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/BF02836471","article-title":"Change of TH1\/TH2 cytokine equilibrium in rats with severe sepsis and therapeutic effect of recombinant interleukin-12 and Shenmai injection","volume":"11","author":"Yu","year":"2005","journal-title":"Chin J Integr Med"},{"key":"B103","first-page":"98","article-title":"[Monocyte response and regulatory effect of emodin and shenmai injection on it in patients with severe sepsis]","author":"Yu","year":"2006","journal-title":"Chin J Integr Tradit Western Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.03.032","article-title":"Efficacy and safety of Shenfu injection for septic shock: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Huang","year":"2019","journal-title":"Am J Emerg Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.05.026","article-title":"Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019","volume":"135","author":"Di Cosimo","year":"2020","journal-title":"Eur J Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e001145","DOI":"10.1136\/jitc-2020-001145","article-title":"On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19","volume":"8","author":"Gambichler","year":"2020","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.577442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T05:14:48Z","timestamp":1604898888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.577442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":110,"alternative-id":["10.3389\/fimmu.2020.577442"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.577442","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"article-number":"577442"}}